TB-500

Source-reported examples · not treatment recommendations

Amount

0.5–1 mg per day

Frequency

Once daily

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Subcutaneous

The stack page gives a different weekly schedule. Evidence about thymosin beta-4 does not automatically validate every product sold as TB-500.

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• FDA's May 2026 scientific assessment, prepared for a July advisory committee meeting, reported that it had not identified human pharmacokinetic, pharmacodynamic or clinical studies of TB-500 by any route. It described major safety-information gaps and concerns about immunogenicity and peptide-related impurities. The document explicitly states that the briefing is not a final agency determination. ^[4]
• A small randomized dry-eye study included nine patients and 18 eyes, with 12 eyes receiving the thymosin beta-4 preparation and six receiving control. It reported symptom and staining signals during follow-up. ^[5]
• A randomized, double-masked study of a full-length thymosin beta-4 ophthalmic solution included 18 patients with neurotrophic keratopathy. Complete healing at four weeks occurred in six of ten treated participants and one of eight placebo participants. The reported comparison had P=.0656. ^[7]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 30 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.

1. Original identification study
2. Original venous-ulcer trial
3. Original metabolism and cell-assay study
4. FDA TB-500 assessment
5. Original nine-patient study
6. Original 72-patient trial
7. Original neurotrophic keratopathy trial
8. FASEB JournalFurther reading · Listed in reference bibliography.
9. Journal of Chromatography A (PubMed)Further reading · Listed in reference bibliography.
10. WADA Scientific ResearchFurther reading · Listed in reference bibliography.
11. Racing Medication & Testing ConsortiumFurther reading · Listed in reference bibliography.
12. Journal of Investigative Dermatology (PubMed)Further reading · Listed in reference bibliography.
13. NCBI BookshelfFurther reading · Listed in reference bibliography.
14. WADA Prohibited ListFurther reading · Listed in reference bibliography.
15. CenterWatch Clinical TrialsFurther reading · Listed in reference bibliography.
16. Nursing Journal (LWW)Further reading · Listed in reference bibliography.
17. University of Michigan HealthFurther reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.